Redeye states that Q4 came in on the weak side and that the outlook for Q1 was weak, but far from catastrophic. We think the stock market has given up on Nepa's ability to 'grow sensibly’, and that it believes that 'steady, profitable growth' will never happen for Nepa. While we think it's up to the management to prove itself profitability-wise, the current valuation leaves a big upside for any positive surprises. Redeye reduces its valuation range.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/